[go: up one dir, main page]

IL207217A - Purified and/or recombinant humanized antibody which binds human c5ar and various aspects related thereto - Google Patents

Purified and/or recombinant humanized antibody which binds human c5ar and various aspects related thereto

Info

Publication number
IL207217A
IL207217A IL207217A IL20721710A IL207217A IL 207217 A IL207217 A IL 207217A IL 207217 A IL207217 A IL 207217A IL 20721710 A IL20721710 A IL 20721710A IL 207217 A IL207217 A IL 207217A
Authority
IL
Israel
Prior art keywords
purified
various aspects
humanized antibody
binds human
aspects related
Prior art date
Application number
IL207217A
Other languages
Hebrew (he)
Other versions
IL207217A0 (en
Original Assignee
G2 Inflammation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2 Inflammation Pty Ltd filed Critical G2 Inflammation Pty Ltd
Publication of IL207217A0 publication Critical patent/IL207217A0/en
Publication of IL207217A publication Critical patent/IL207217A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL207217A 2008-02-20 2010-07-26 Purified and/or recombinant humanized antibody which binds human c5ar and various aspects related thereto IL207217A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6653908P 2008-02-20 2008-02-20
PCT/AU2009/000184 WO2009103113A1 (en) 2008-02-20 2009-02-19 HUMANIZED ANTI-C5aR ANTIBODIES

Publications (2)

Publication Number Publication Date
IL207217A0 IL207217A0 (en) 2010-12-30
IL207217A true IL207217A (en) 2015-03-31

Family

ID=40984994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207217A IL207217A (en) 2008-02-20 2010-07-26 Purified and/or recombinant humanized antibody which binds human c5ar and various aspects related thereto

Country Status (14)

Country Link
US (3) US8268972B2 (en)
EP (2) EP2826791A3 (en)
JP (2) JP2011515073A (en)
KR (1) KR20100117120A (en)
CN (2) CN101970494B (en)
AU (1) AU2009217224B2 (en)
BR (1) BRPI0907532A2 (en)
CA (1) CA2714296A1 (en)
ES (1) ES2562627T3 (en)
IL (1) IL207217A (en)
MX (1) MX2010009190A (en)
RU (1) RU2010138612A (en)
WO (1) WO2009103113A1 (en)
ZA (1) ZA201005348B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2561828T3 (en) 2002-01-25 2016-03-01 Novo Nordisk A/S Monoclonal antibodies against C5aR extracellular loops
ZA200900954B (en) * 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
BRPI0907532A2 (en) 2008-02-20 2015-07-28 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
EP2297203A1 (en) 2008-06-30 2011-03-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
BRPI0918947A2 (en) * 2008-09-26 2015-12-01 Ucb Pharma Sa antibody fusion protein
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
JP2013520476A (en) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス Stable antibody-containing composition
PT2542257T (en) 2010-03-01 2017-10-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN102905692B (en) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 Comprise the stable multi-dose compositions of antibody and antiseptic
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
BR112013031198B1 (en) 2011-06-06 2020-10-20 Novo Nordisk A/S c5ar binding antibody and its use
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
CN105392803B (en) * 2013-05-08 2019-12-06 诺和诺德股份有限公司 Use of C5aR antagonists
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
EP3636073B1 (en) * 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
PL3221359T3 (en) 2014-11-17 2020-11-16 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
KR20170094787A (en) * 2014-12-18 2017-08-21 에프. 호프만-라 로슈 아게 Assay and method for determining cdc eliciting antibodies
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
CN106957366B (en) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 C5aR antibody and preparation method and application thereof
CA3057146A1 (en) * 2017-03-23 2018-09-27 The Trustees Of The University Of Pennsylvania Anti-c5a antibodies and uses thereof
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
JP6511200B1 (en) * 2017-12-14 2019-05-15 硬化クローム工業株式会社 Cooling roll and method of manufacturing thermoplastic resin sheet using the same
KR20210018906A (en) * 2018-06-07 2021-02-18 케모센트릭스, 인크. Administration and effects of C5A antagonists on ANCA-associated vasculitis
KR20210054528A (en) 2018-08-31 2021-05-13 리제너론 파아마슈티컬스, 인크. Dosing strategies to alleviate cytokine release syndrome against CD3/C20 bispecific antibodies
CN109439662B (en) * 2018-11-15 2020-09-01 北京大学第三医院 sgRNA for C5aR1 gene knockout, vector, construction method and detection method
BR112021017860A2 (en) 2019-03-14 2021-12-07 Morphosys Ag Isolated antibody or antibody fragment specific to human c5ar, nucleic acid composition, vector composition, host cell and pharmaceutical composition
US11773179B2 (en) * 2020-01-13 2023-10-03 Visterra, Inc. Antibody molecules to C5aR1 and uses thereof
MX2023008302A (en) 2021-01-13 2023-09-25 Visterra Inc Humanized complement 5a receptor 1 antibodies and methods of use thereof.
WO2024193714A1 (en) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 Cell immunotherapy composition and method

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (en) 1989-01-03 1990-10-25 Merck & Co Inc Purified c5a receptor from human polymorphonuclear leukocyte
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) * 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
JPH08504320A (en) 1992-09-25 1996-05-14 コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼーション Target binding polypeptide
PT752248E (en) 1992-11-13 2001-01-31 Idec Pharma Corp THERAPEUTIC APPLICATION OF QUIMERIC ANTIBODIES AND RADIOACTIVELY MARKING OF ANTIGENES OF RESTRICTED DIFFERENTIATION OF HUMAN LYMPHOCYTE B FOR THE TREATMENT OF B-CELL LYMPHOMA
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (en) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd Anti-c5a receptor antibody, its production and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
MX9709338A (en) 1995-06-05 1998-02-28 Incyte Pharma Inc A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR.
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
JP2001511645A (en) 1997-01-31 2001-08-14 インサイト・ファーマスーティカルズ・インコーポレイテッド Human C5a-like receptor
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc SINGLE CHAIN PROTEINS FIXING ANTIGENS CAPABLE OF GLYCOSYLATION, PRODUCTION AND USES THEREOF
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
ES2389251T3 (en) 2000-12-19 2012-10-24 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
ATE453661T1 (en) 2001-09-27 2010-01-15 Merck & Co Inc ISOLATED DNA MOLECULES ENCODING A HUMANIZED CALCITONIN GENE-RELATED PEPTIDE RECEPTOR, RELATED NON-HUMAN TRANSGENIC ANIMALS AND ASSAY METHODS
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
ES2561828T3 (en) * 2002-01-25 2016-03-01 Novo Nordisk A/S Monoclonal antibodies against C5aR extracellular loops
US20060134109A1 (en) 2002-09-09 2006-06-22 Nura Inc. G protein coupled receptors and uses thereof
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007534631A (en) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ Laminin-5γ2 binding peptides, related compositions and uses thereof
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
BRPI0509264A (en) * 2004-03-26 2007-09-04 Promics Pty Ltd treatment of neurological conditions using complement c5a receptor modulators
CN101218256B (en) 2005-03-23 2017-04-19 根马布股份公司 Antibodies against cd38 for treatment of multiple myeloma
US7649951B2 (en) 2006-08-16 2010-01-19 Harris Corporation System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
JP2010501165A (en) 2006-08-22 2010-01-21 ジーツー インフラメイション プロプライエタリー リミテッド Antibody production method
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2009053368A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
BRPI0907532A2 (en) 2008-02-20 2015-07-28 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
JP2013520476A (en) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス Stable antibody-containing composition
CN102905692B (en) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 Comprise the stable multi-dose compositions of antibody and antiseptic

Also Published As

Publication number Publication date
RU2010138612A (en) 2012-03-27
CN104193824A (en) 2014-12-10
ZA201005348B (en) 2011-10-26
EP2254911A4 (en) 2011-10-19
US20130129721A1 (en) 2013-05-23
KR20100117120A (en) 2010-11-02
CA2714296A1 (en) 2009-08-27
BRPI0907532A2 (en) 2015-07-28
JP2014193164A (en) 2014-10-09
US8361468B2 (en) 2013-01-29
CN101970494B (en) 2015-01-21
EP2826791A3 (en) 2015-07-29
MX2010009190A (en) 2010-09-10
US8808701B2 (en) 2014-08-19
EP2826791A2 (en) 2015-01-21
AU2009217224B2 (en) 2014-09-11
US20120315275A1 (en) 2012-12-13
WO2009103113A1 (en) 2009-08-27
ES2562627T3 (en) 2016-03-07
IL207217A0 (en) 2010-12-30
JP6034826B2 (en) 2016-11-30
JP2011515073A (en) 2011-05-19
EP2254911B1 (en) 2015-11-25
US20110190477A1 (en) 2011-08-04
AU2009217224A1 (en) 2009-08-27
EP2254911A1 (en) 2010-12-01
US8268972B2 (en) 2012-09-18
CN101970494A (en) 2011-02-09

Similar Documents

Publication Publication Date Title
IL207217A (en) Purified and/or recombinant humanized antibody which binds human c5ar and various aspects related thereto
IL266039A (en) Humanized anti-factor d antibodies and uses thereof
HK1223114A1 (en) Anti-factor xi monoclonal antibodies and methods of use thereof xi
HRP20181969T1 (en) Humanized anti-factor d antibodies and uses thereof
HRP20181616T1 (en) Fully human anti-vap-1 monoclonal antibodies
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL211742A (en) Isolated monoclonal antibody that specifically binds human frizzled receptors and various aspects related thereto
IL220723A0 (en) Compositions of humanized notch fusion proteins and methods of treatment
HK1154251A1 (en) Humanized antibodies against human interferon alpha
IL214755A (en) Anti-rhd monoclonal antibody and various aspects related thereto
HK1158977A1 (en) Anti-ferroportin monoclonal antibodies and uses thereof
EP2484694A4 (en) Monoclonal antibody against human hig-1 polypeptide
EP2540742A4 (en) Anti-cyr61 protein monoclonal antibodies and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees